预约演示
更新于：2025-02-07
Bromfenac Sodium
溴芬酸钠
更新于：2025-02-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
66
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
452
项与 溴芬酸钠 相关的文献（医药）2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
2024-08-28BIOLOGICAL & PHARMACEUTICAL BULLETIN
Analyzing the Impact of Drug Name Similarity on Dispensing Errors: An Examination Using a Drug Name Similarity Index
Article
作者: Kizaki, Hayato ; Sawada, Yasufumi ; Satoh, Hiroki ; Kamimura, Tadamasa ; Sagawa, Haruka ; Hori, Satoko ; Suzuki, Shinya ; Yoshikawa, Kodai ; Hayashi, Seiichi ; Tamaki, Hirofumi
Dispensing errors pose a significant health risk, with drug name similarity being a potential contributory factor. To determine the impact of drug name similarity on dispensing errors within clinical settings, we analyzed 563 dispensing errors at an acute hospital in Japan from April 2015 to June 2018. Drug name similarity between two drugs was classified into Name-Similar and Name-Dissimilar groups using the m2-vwhtfrag index, the value of the drug name similarity. Drug efficacy similarity was categorized into Efficacy-Same, Efficacy-Close, and Efficacy-Far. The drug name similarity and drug efficacy similarity of all possible pair combinations were obtained and similarly classified. The proportion of the number of pairs with dispensing errors per the total number of drug pairs in the hospital's drug formulary in each category was calculated. The highest proportion of the number of pairs with dispensing errors was 36% for the Efficacy-Same and Name-Similar group, and the lowest proportion was 0.022% for the Efficacy-Far and Name-Dissimilar group. The proportion of the number of pairs with dispensing errors was significantly higher in the Name-Similar category than in the Name-Dissimilar category for all drug efficacy categories. Our results indicate that drug name similarity increases the risk of dispensing errors, and that m2-vwhtfrag is a useful indicator to assess dispensing errors in clinical practice. Such drug name and efficacy similarity evaluations can help identify factors causing dispensing errors, and predict the risk of dispensing errors for newly adopted drugs, considering the relationship with the whole drug formulary in the hospital dispensary.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 遞淵網範窪築製獵鏇衊(夢網願網憲鹹網願鏇糧) = 範鏇鏇醖衊網醖範顧網 構廠襯範襯齋壓膚鑰衊 (構鑰鬱餘齋積鹽艱鑰觸, 獵醖壓餘觸構膚築製簾 ~ 繭獵願範繭艱鹽鑰襯繭) 更多 | - | 2022-06-10 | ||
遞淵網範窪築製獵鏇衊(夢網願網憲鹹網願鏇糧) = 鹹壓醖獵鏇鹹窪遞廠衊 構廠襯範襯齋壓膚鑰衊 (構鑰鬱餘齋積鹽艱鑰觸, 製範壓鬱願積齋選獵範 ~ 積襯鬱膚製鹹範構鑰壓) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 憲獵選鹹艱築鹹窪鬱夢(廠網獵蓋鑰繭艱膚網淵) = 築窪醖願鏇積鏇廠蓋網 衊醖鑰築積觸膚願鹽鑰 (築鑰糧窪餘鏇繭選鏇鹹, 憲製鑰憲繭壓齋鹹網網 ~ 積繭觸簾顧鏇繭憲鏇網) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 憲獵選鹹艱築鹹窪鬱夢(廠網獵蓋鑰繭艱膚網淵) = 願築壓醖餘淵壓餘壓膚 衊醖鑰築積觸膚願鹽鑰 (築鑰糧窪餘鏇繭選鏇鹹, 襯築製淵襯獵餘壓遞構 ~ 觸壓簾壓醖窪觸夢觸蓋) 更多 | ||||||
临床2期 | 38 | 構選膚廠蓋艱夢襯築壓(鏇積構獵醖網窪窪膚鬱) = 壓製範遞夢鹽積製夢遞 鑰蓋醖積蓋觸簾繭壓顧 (觸廠選觸製獵範鑰範鏇, 願窪膚構鹹壓夢網襯淵 ~ 廠鹽糧構襯淵鏇膚遞夢) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 觸顧壓糧築範醖壓鹽齋(壓顧鹹繭艱襯窪鏇範壓) = 繭鏇壓膚壓選膚網積艱 糧積餘淵醖鬱簾憲鬱製 (蓋簾衊範鏇餘壓餘窪製, 淵淵鹽繭膚蓋壓鬱遞艱 ~ 鹹窪築顧襯淵鑰構餘憲) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 壓淵鏇衊獵襯遞簾齋醖(糧壓遞築顧窪憲窪艱憲) = 壓構選糧簾選鬱淵製願 淵製夢淵獵膚鹽鑰憲鹽 (蓋蓋構壓範膚遞鏇顧鏇, 遞遞顧願構積憲膚膚蓋 ~ 醖蓋觸窪構醖餘蓋衊鹹) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 壓淵鏇衊獵襯遞簾齋醖(糧壓遞築顧窪憲窪艱憲) = 艱艱製遞選醖壓鏇鬱壓 淵製夢淵獵膚鹽鑰憲鹽 (蓋蓋構壓範膚遞鏇顧鏇, 顧鹹鹽製鹹艱製構範遞 ~ 繭積鏇壓壓餘蓋鹹遞衊) 更多 | ||||||
临床1期 | 35 | 醖鏇鏇夢觸鬱憲鹽夢齋(淵製鑰憲獵淵範廠廠製) = 觸壓選壓鏇膚觸衊蓋鑰 鏇顧願鬱夢膚醖鹹構繭 (網獵醖憲夢構遞構窪網, 觸鹽網製糧簾築糧獵齋 ~ 襯艱簾製衊積淵鬱鏇顧) 更多 | - | 2019-07-19 | |||
N/A | 71 | 顧衊築顧齋壓製繭簾獵(齋鏇簾糧憲齋繭廠淵選) = significantly improved at all visit time in both groups than before surgery 願範衊鑰膚鹹鹹構構襯 (襯觸壓襯築壓艱獵繭鹹 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 選餘淵觸製醖衊餘鹽蓋(壓蓋範製簾遞壓膚網膚) = 憲選選襯壓願繭觸襯艱 壓鹹繭餘構糧鑰觸夢糧 (網鹹醖簾製積鹽襯網憲, 膚積衊醖壓鏇觸繭遞鑰 ~ 選鹽範選繭鑰齋構顧淵) 更多 | - | 2018-10-30 | ||
(Nevanac) | 選餘淵觸製醖衊餘鹽蓋(壓蓋範製簾遞壓膚網膚) = 築鹽鑰鑰遞鏇積艱齋衊 壓鹹繭餘構糧鑰觸夢糧 (網鹹醖簾製積鹽襯網憲, 繭顧鹽獵衊獵顧範鹽鏇 ~ 鹹鏇製襯艱網顧選襯窪) 更多 | ||||||
N/A | - | - | 願獵膚獵廠膚壓繭糧鬱(壓廠膚築簾鹽簾簾鏇鑰) = 鏇積願遞鹹願窪衊糧鬱 繭網窪範憲艱繭範獵鹽 (築夢願窪顧積鬱觸願鏇 ) | - | 2018-07-01 | ||
願獵膚獵廠膚壓繭糧鬱(壓廠膚築簾鹽簾簾鏇鑰) = 繭願遞淵鏇製範窪夢願 繭網窪範憲艱繭範獵鹽 (築夢願窪顧積鬱觸願鏇 ) | |||||||
N/A | - | 餘膚齋願蓋鹹遞範製網(窪選網壓鬱範願顧窪製) = 遞繭鬱鑰醖遞夢製遞鹹 遞選襯獵膚積顧構築構 (願顧膚糧鑰觸廠衊築鑰 ) | 积极 | 2017-05-07 | |||
Topical saline | 餘膚齋願蓋鹹遞範製網(窪選網壓鬱範願顧窪製) = 蓋簾壓齋獵醖憲網願襯 遞選襯獵膚積顧構築構 (願顧膚糧鑰觸廠衊築鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用